Want to see HK:2552 full AI Analyst Report?

Hua Medicine (2552) Price & Analysis

4 Followers

2552 Stock Chart & Stats

HK$2.52

-HK$0.02(-0.79%)

At close: Jul 27 4:00 PM EDT

HK$2.52

-HK$0.02(-0.79%)

Day’s Range― - ―

52-Week RangeHK$1.97 - HK$4.95

Previous CloseN/A

Volume865.87K

Average Volume (3M)6.34M

Market Cap

HK$2.26B

Enterprise ValueHK$2.19K

Total Cash (Recent Filing)HK$1.09B

Total Debt (Recent Filing)HK$301.80M

Price to Earnings (P/E)1.8

Beta1.40

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.13

Shares Outstanding1,056,605,000

10 Day Avg. Volume6,422,209

30 Day Avg. Volume6,335,350

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)2.71

Price to Sales (P/S)5.69

P/FCF Ratio-45.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.06

Revenue Forecast (FY)HK$1.04B

Bulls Say, Bears Say

Bulls Say

First‑in‑class Drug & Focused FranchiseHaving a first‑in‑class marketed therapy establishes a durable competitive position in diabetes care: it supports physician adoption, creates a clinical and regulatory moat, and enables a focused commercial model. This foundation increases the odds of sustained prescription demand and expands the value of pipeline extensions over months.

Accelerating Revenue And Improving Gross MarginSharp revenue acceleration and a ~56.9% gross margin indicate stronger unit economics and better pricing or mix. Durable gross margin improvement suggests product-level profitability that can support future scale and operating leverage if SG&A growth is controlled, improving long‑term margin sustainability.

Improved Balance Sheet FlexibilityRestoring positive equity and modest debt-to-equity (~0.30) materially reduces solvency risk versus 2024. This stronger balance sheet provides durable flexibility to fund commercialization, R&D, or partnership initiatives without immediate refinancing, supporting multi‑month operational resilience.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicate the business is burning cash despite revenue gains. Over a multi‑month horizon this raises funding and execution risks, increases reliance on balance‑sheet resources or external capital, and undermines confidence in internally financed growth.

Weak Operating Profitability / Earnings QualityA large gap between negative operating margins and positive net income suggests earnings are driven by non‑operating items rather than recurring operations. This reduces profit quality and the repeatability of results, making near‑term margin improvement and sustainable profitability uncertain.

Concentration On Single Product RevenueHeavy dependence on one marketed drug concentrates regulatory, reimbursement, and competitive risk. Any pricing pressure, formulary shifts, or new entrants in the next months could materially affect revenue, since diversification from additional indications or products remains limited and will take time to develop.

Hua Medicine News

Hua Medicine Issues Profit Warning as One-Off Bayer Gain Drops Out

An update from Hua Medicine ( ($HK:2552) ) is now available. Hua Medicine has warned shareholders that it...

17h ago

Hua Medicine Shareholders Approve All AGM Resolutions, Renew Capital Mandates

Hua Medicine ( ($HK:2552) ) has issued an update. Shareholders of Hua Medicine approved all resolutions at the...

1M ago

Hua Medicine Sets New Board and Committee Line-Up Effective June 2026

The latest update is out from Hua Medicine ( ($HK:2552) ). Hua Medicine has announced the composition of...

1M ago

Hua Medicine Formalizes Nomination Committee Governance and Diversity Framework

Hua Medicine ( ($HK:2552) ) has provided an announcement. Hua Medicine has formalized the terms of reference for...

1M ago

Hua Medicine Strengthens Governance with New Nomination Committee Appointments

Hua Medicine ( ($HK:2552) ) has provided an announcement. Hua Medicine has appointed executive director Dr. Yi Zhang...

1M ago

Hua Medicine Sets 2026 AGM to Approve Accounts and Renew Capital Mandates

An update from Hua Medicine ( ($HK:2552) ) is now available. Hua Medicine has called its annual general...

4M ago

Hua Medicine Seeks Shareholder Approval for Digital-Friendly Articles Update

The latest announcement is out from Hua Medicine ( ($HK:2552) ). Hua Medicine plans to update its constitutional...

4M ago

Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin

An announcement from Hua Medicine ( ($HK:2552) ) is now available. Hua Medicine reported rapid commercial growth in...

4M ago

Hua Medicine Reshuffles Company Secretary and Authorised Representative Roles

Hua Medicine ( ($HK:2552) ) just unveiled an update. Hua Medicine has announced a change in its corporate...

4M ago

Hua Medicine Relocates Hong Kong Principal Place of Business

Hua Medicine ( ($HK:2552) ) has shared an announcement. Hua Medicine has announced that it will relocate its...

5M ago

2552 FAQ

What was Hua Medicine Ltd.’s price range in the past 12 months?

Hua Medicine Ltd. lowest stock price was HK$1.97 and its highest was HK$4.95 in the past 12 months.

What is Hua Medicine Ltd.’s market cap?

Hua Medicine Ltd.’s market cap is HK$2.26B.

When is Hua Medicine Ltd.’s upcoming earnings report date?

Hua Medicine Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 13 days.

How were Hua Medicine Ltd.’s earnings last quarter?

Hua Medicine Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Hua Medicine Ltd. overvalued?

According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Hua Medicine Ltd. pay dividends?

Hua Medicine Ltd. does not currently pay dividends.

What is Hua Medicine Ltd.’s EPS estimate?

Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hua Medicine Ltd. have?

Hua Medicine Ltd. has 1,056,605,000 shares outstanding.

What happened to Hua Medicine Ltd.’s price movement after its last earnings report?

Hua Medicine Ltd. reported an EPS of -HK$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.634%.

Which hedge fund is a major shareholder of Hua Medicine Ltd.?

Currently, no hedge funds are holding shares in HK:2552

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hua Medicine Ltd.

Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.